Analysis of taurolidine as a preventive solution for CIED infection: Preliminary results from a single centre

Objective: Cardiac implantable electronic device (CIED) infection is the most devastating adverse event related to any invasive CIED procedure.Our study investigates the adjunct use of a novel taurolidine containing antimicrobial solution during cardiac implantable electronic device placement to prevent cardiac implantable elect ronic device infection.Methods: The authors prospectively evaluate all consecutive CIED procedures performed with adjunct use of the taurolidine containing antimicrobial adjunct in our centre.Cardiac implantable electronic device, procedure and patient related risk factors are recorded.Primary endpoint was major CIED infection.Patients were followed -up three months after implantation for acute CIED infections and one year after for subacute CIED infections.Results: From September 2023 to January 2024, 26 high-risk CIED procedures were conducted with the taurolidinebased antimicrobial adjunct.Throughout the 3-month follow-up period, no infections were observed.Additionally, only one adverse event related to the CIED was recorded, with no adverse e vents of any severity related to the procedures or the antimicrobial adjunct, nor was any all-cause mortality reported during the follow-up period.Conclusions: The use of the taurolidine containing antimicrobial adjunct for any CIED procedure is safe.No adverse event in relation could be recorded.